Avalo Therapeutics, Inc.AVTXNASDAQ
Loading
Free Cash Flow Growth Under PressureDecelerating
Percentile Rank33
Studio
Year-over-Year Change

Year-over-year free cash flow growth rate

Percentile
P33
Within normal range
vs 2Y Ago
-0.9x
Contraction
Streak
2 yr
Consecutive declineDecelerating
PeriodValue
2024-59.08%
2023-14.87%
202262.19%
2021-74.88%
2020-109.33%
2019-425.29%
2018-129.55%
2017185.54%
2016-43.45%
201534.46%